AnaptysBio, Inc. (ANAB)
NASDAQ: ANAB · Real-Time Price · USD
68.99
-0.29 (-0.42%)
May 6, 2026, 2:15 PM EDT - Market open
AnaptysBio Stock Forecast
Stock Price Forecast
The 12 analysts that cover AnaptysBio stock have a consensus rating of "Buy" and an average price target of $71.5, which forecasts a 3.64% increase in the stock price over the next year. The lowest target is $20 and the highest is $100.
Price Target: $71.5 (+3.64%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for AnaptysBio stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Buy | 6 | 6 | 6 | 5 | 6 | 6 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 12 | 12 | 11 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $95 → $93 | Buy | Maintains | $95 → $93 | +34.80% | May 4, 2026 |
| Leerink Partners | Leerink Partners | Buy Maintains $66 → $85 | Buy | Maintains | $66 → $85 | +23.21% | Apr 28, 2026 |
| Barclays | Barclays | Buy Maintains $79 → $63 | Buy | Maintains | $79 → $63 | -8.68% | Apr 22, 2026 |
| UBS | UBS | Strong Buy Maintains $90 → $60 | Strong Buy | Maintains | $90 → $60 | -13.03% | Apr 21, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $67 → $95 | Buy | Maintains | $67 → $95 | +37.70% | Mar 31, 2026 |
Financial Forecast
Revenue This Year
150.33M
from 234.60M
Decreased by -35.92%
Revenue Next Year
213.10M
from 150.33M
Increased by 41.75%
EPS This Year
-3.75
from -0.46
EPS Next Year
-4.09
from -3.75
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 175.4M | 247.8M | ||||||
| Avg | 150.3M | 213.1M | ||||||
| Low | 130.0M | 172.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -25.3% | 64.8% | ||||||
| Avg | -35.9% | 41.8% | ||||||
| Low | -44.6% | 15.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 0.70 | 0.09 | ||||||
| Avg | -3.75 | -4.09 | ||||||
| Low | -6.52 | -8.38 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.